CGRP-REZEPTOR-ANTAGONISTEN

European patent · EP3368525 · In force

Register entry

Publication number: EP3368525
Application number: EP16791443
Kind: European patent with effect for Switzerland and Liechtenstein
Status: In force
Specification: Granted
Filed: Oct 28, 2016
Published: Sep 5, 2018
Granted: Mar 13, 2019
Protection ends at the latest: Oct 27, 2036
Next annual fee due: Oct 31, 2026
IPC classes: C07D 401/14 (2006.01)
C07D 498/10 (2006.01)
A61K 31/437 (2006.01)
A61K 31/537 (2006.01)
A61P 25/06 (2006.01)
Priority: GB 201519196 30.10.2015
PCT application: PCT/IB2016/056517 28.10.2016
PCT publication: WO2017/072721 04.05.2017
Filing language: English
Source: Swissreg

What the Federal Institute of Intellectual Property published about this title, newest first.

Nov 1, 2025
Change
Published in Swissreg on 01.11.2025
Nov 1, 2024
Change
Published in Swissreg on 01.11.2024
Oct 30, 2024
Holder’s address changed
Owner
Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom → Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom
Published in Swissreg on 30.10.2024
Jan 26, 2024
Change
Published in Swissreg on 26.01.2024
Nov 1, 2022
Change
Published in Swissreg on 01.11.2022
Feb 14, 2020
Address changed
Representative
TR-IP Consulting LLC, Route de Coutset 18, 1485 Nuvilly → TR-IP Consulting LLC, Route du Coutset 18, 1485 Nuvilly
Published in Swissreg on 14.02.2020
Apr 25, 2019
Agent entered
Representative
TR-IP Consulting LLC, Route de Coutset 18, 1485 Nuvilly
Published in Swissreg on 25.04.2019
Mar 13, 2019
Granted
Published in Swissreg on 13.03.2019

Granta Park Great Abington, Cambridge CB21 6DG, GB

TR-IP Consulting LLC

Route du Coutset 18, 1485 Nuvilly